May 19, 2020
NIH begins clinical trial of hydroxychloroquine, azithromycin for COVID-19 treatment
Editor's Note
The National Institutes of Health (NIH) on May 14 announced that it is enrolling adults with mild to moderate COVID-19 in a study of treatment with hydroxychloroquine and azithromycin.
The Phase 2b trial is enrolling around 2,000 adults across the US. Participants must have confirmed infection with SARS-CoV-2 and be experiencing fever, cough, and/or shortness of breath.
The participants will be randomly assigned to short-term treatment with either hydroxychloroquine and azithromycin or matching placebos.
Free Daily News
- Workshop: Mastering The Joint Commission standards and CMS regulations
- Workshop: The leadership shift—From managing tasks to leading with influence
- Simulation-based robotic surgery training boosts team confidence, communication
- Perioperative leaders gather at 2025 OR Manager Conference
- CMS launches 6-year model to curb wasteful Medicare spending with AI-driven reviews
- Report: Hospitals can cut anesthesia costs, burnout through tech-driven partnerships
- Study: One in four US healthcare workers faces food insecurity
- Digital decision aid boosts shared decision-making in knee replacement consultations
- CMS narrows surveys to immediate jeopardy, harm during shutdown
- Ambient AI turns burnout relief into 'hard ROI' at Seattle Children’s
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement